

Hybrigenics' broad-spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses

Paris, France, on March 26th, 2018 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Euronext Growth market of Euronext Paris, with a focus on research and development of new anticancer treatments, announces today the publication by a group of German researchers of the antiviral activity against human adenoviruses of a broad-spectrum inhibitor of Ubiquitin-Specific Proteases (USPs) discovered and patented by Hybrigenics.

Human adenoviruses cause generally benign ocular, respiratory or gastrointestinal infections. However, in immuno-compromised patients such as the recipients of a bone marrow graft, some adenoviral infections can become severe, even fatal. In addition, a few adenoviral types are especially transmissible or pathogenic inducing epidemic kerato-conjunctivitis or pneumonia, respectively.

A team of researchers from the Institutes of Virology of Hamburg and Hannover in Germany have tested HBX 47,939, Hybrigenics' proprietary broad-spectrum inhibitor of USPs, on cell cultures infected *in vitro* by one of 9 prototype strains or 4 clinical isolates of human adenoviruses (Kosulin *et al.*, 2018, Antiviral Therapy, doi: 10.3851/IMP3230). On 11 out of the 13 viral types tested, HBX 47,939 was shown to inhibit viral replication in the infected cells and to decrease the production of new virions released in the culture medium. The authors conclude: *"These results point to HBX 47,939 as a promising broad-spectrum anti-adenoviral drug, opening new opportunities to prevent severe adenoviral infections and to improve their treatment."*

"Beyond oncology, these findings about the antiviral properties of one of our inhibitors of Ubiquitin-Specific Proteases represent a potential upside to our drug discovery program," said Remi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on the Euronext Growth market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases.

Hybrigenics' development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Inecalcitol has been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. Two clinical Phase II studies of inecalcitol are currently ongoing in chronic myeloid leukemia and acute myeloid leukemia. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics' research program is exploring the role of enzymes called Ubiquitin-Specific Proteases (USP) in the balance between degradation and recycling of proteins called onco-proteins due to their involvement in various cancers. Hybrigenics is evaluating the interest of inhibitors of USP as anti-cancer drug candidates. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug.

Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.



Hybrigenics is listed on the Euronext Growth market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap

Financial communication

Julien Perez / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.eu